Effective targeting of primitive AML CD34+ cells by the second-generation proteasome inhibitor carfilzomib

British Journal of Haematology

Volumn 171, Issue 4, 2015, Pages 652-655

  van der Helm, Lieke H ^a   Bosman, Matthieu C J ^a   Schuringa, Jan J ^a   Vellenga, Edo ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Acute leukaemia; Bortezomib; Carfilzomib; Oprozomib; Stem cells

Indexed keywords

BORTEZOMIB; CARFILZOMIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OPROZOMIB; PROTEASOME; PROTEIN MCL 1; ENHANCED GREEN FLUORESCENT PROTEIN; GREEN FLUORESCENT PROTEIN; OLIGOPEPTIDE; PROTEASOME INHIBITOR; TUMOR PROTEIN;

ACUTE MYELOBLASTIC LEUKEMIA; CANCER CELL CULTURE; CANCER CELL LINE; CD34+ CELL; CELL SURVIVAL; COLONY FORMING CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LETTER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; UPREGULATION; DRUG SCREENING; GENETICS; HL 60 CELL LINE; METABOLISM; PATHOLOGY; REPORTER GENE; TUMOR CELL CULTURE; TUMOR STEM CELL ASSAY;

BORTEZOMIB; DRUG SCREENING ASSAYS, ANTITUMOR; GENES, REPORTER; GREEN FLUORESCENT PROTEINS; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; NEOPLASM PROTEINS; OLIGOPEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PROTEOLYSIS; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 84945490194     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13418     Document Type: Letter

References (10)

1. Bonardi, F., Fusetti, F., Deelen, P., van Gosliga, D., Vellenga, E. & Schuringa, J.J. (2013) A proteomics and transcriptomics approach to identify leukemic stem cell (LSC) markers. Molecular & Cellular Proteomics, 12, 626-637.
2. Bosman, M.C., Schuringa, J.J., Quax, W.J. & Vellenga, E. (2013) Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-kappaB and the accumulation of MCL-1. Experimental Hematology, 41, 530-538.
3. Bosman, M.C., Schepers, H., Jaques, J., Brouwers-Vos, A.Z., Quax, W.J., Schuringa, J.J. & Vellenga, E. (2014) The TAK1-NF-kappaB axis as therapeutic target for AML. Blood, 124, 3130-3140.
4. Crawford, L.J. & Irvine, A.E. (2013) Targeting the ubiquitin proteasome system in haematological malignancies. Blood Reviews, 27, 297-304.
5. Guzman, M.L., Neering, S.J., Upchurch, D., Grimes, B., Howard, D.S., Rizzieri, D.A., Luger, S.M. & Jordan, C.T. (2001) Nuclear factor-κB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood, 98, 2301-2307.
6. Kagoya, Y., Yoshimi, A., Kataoka, K., Nakagawa, M., Kumano, K., Arai, S., Kobayashi, H., Saito, T., Iwakura, Y. & Kurokawa, M. (2014) Positive feedback between NF-kappaB and TNF-alpha promotes leukemia-initiating cell capacity. The Journal of Clinical Investigation, 124, 528-542.
7. Kortuem, K.M. & Stewart, A.K. (2013) Carfilzomib. Blood, 121, 893-897.
8. Kumatori, A., Tanaka, K., Inamura, N., Sone, S., Ogura, T., Matsumoto, T., Tachikawa, T., Shin, S. & Ichihara, A. (1990) Abnormally high expression of proteasomes in human leukemic cells. Proceedings of the National Academy of Sciences of the United States of America, 87, 7071-7075.
9. Ma, W., Kantarjian, H., Bekele, B., Donahue, A.C., Zhang, X., Zhang, Z.J., O'Brien, S., Estey, E., Estrov, Z., Cortes, J., Keating, M., Giles, F. & Albitar, M. (2009) Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome. Clinical Cancer Research, 15, 3820-3826.
10. Rhyasen, G.W., Bolanos, L., Fang, J., Jerez, A., Wunderlich, M., Rigolino, C., Mathews, L., Ferrer, M., Southall, N., Guha, R., Keller, J., Thomas, C., Beverly, L.J., Cortelezzi, A., Oliva, E.N., Cuzzola, M., Maciejewski, J.P., Mulloy, J.C. & Starczynowski, D.T. (2013) Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. Cancer Cell, 24, 90-104.